Newsroom | 26651 results

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the primary analysis of the Phase 2 RAMP 201 clinical trial was published online in the Journal of Clinical Oncology (JCO). The data reported in the publication showed that avutometinib plus defactinib demonstrated a confirmed overall response rate (ORR) of 31% in all patients with recurrent low-grade...

PARSIPPANY, N.J.--(BUSINESS WIRE)--AdvanSix To Release Second Quarter Financial Results And Hold Investor Conference Call On August 1...

VANCOUVER, British Columbia--(BUSINESS WIRE)--Life Sciences BC Announces 2025 Awards Winners, Honouring Excellence in Health Innovation...

PHILADELPHIA--(BUSINESS WIRE)--GSK begins shipping influenza vaccine doses for the 2025-26 flu season....

PALM BEACH GARDENS, Fla.--(BUSINESS WIRE)--Eolas Therapeutics today announced that it has entered into a new agreement with AstraZeneca to assume full development rights to AZD4041, an investigational therapy targeting the orexin-1 receptor, for the treatment of opioid use disorder (OUD) and other substance use disorders. Terms of the agreement are confidential. AZD4041 is a highly selective orexin-1 receptor antagonist that was being co-developed by Eolas and AstraZeneca with support from the...

CAMBRIDGE, Angleterre--(BUSINESS WIRE)--Trois équipes d'élèves issus d'écoles européennes ont remporté des prix lors du concours scientifique Cambridge 2025, organisé par le groupe International Education de Cambridge University Press & Assessment (Cambridge). Les équipes gagnantes, originaires de Turquie, d'Ukraine et de République tchèque, ont été sélectionnées par un jury d'experts de l'université de Cambridge pour la qualité de leurs projets, qui visent tous à relever des défis concrets...

CAMBRIDGE, Inglaterra--(BUSINESS WIRE)--Tres equipos de estudiantes de centros educativos de toda Europa han sido premiados en la 2025 Cambridge Science Competition, organizada por el grupo de educación internacional de Cambridge University Press & Assessment (Cambridge). Los equipos ganadores proceden de Turquía, Ucrania y la República Checa y los ha seleccionado un jurado de expertos de la Universidad de Cambridge por la calidad de sus proyectos, cada uno de los cuales aborda cuestiones d...

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today provided an operational update and released financial results for the fiscal year ended April 30, 2025. “The FDA approval of EKTERLY represents a major milestone—not only as the first commercial product for KalVista, but more importantly, as the first and only oral on-demand therapy for people living with HAE,” said Ben Palleiko, CEO of KalVista Pharmaceuticals. “EKTERLY delivers a long-...

BERKELEY, Calif.--(BUSINESS WIRE)--Renasant Bio (Renasant), announced its launch today to advance next-generation disease-modifying treatments for autosomal dominant polycystic kidney disease (ADPKD), the leading genetic cause of end-stage renal failure. Renasant is developing a pipeline of oral small molecule corrector and first-in-class potentiator therapies that directly target the underlying biology of ADPKD, with the goal of restoring the function of key polycystin proteins across multiple...

TOULOUSE, France & DURHAM, N.C.--(BUSINESS WIRE)--Micropep Technologies, a global leader in micropeptide technology for sustainable crop protection, today announced the appointment of Georg Goeres as Chief Executive Officer effective July 1, 2025. Goeres is the former head of the Biologicals Business Unit at Indigo Agriculture and has over 20 years of international leadership experience in agriculture, having worked across Europe, Africa, the U.S., and Latin America. Goeres succeeds Micropep fo...